How AbbVie tries to fend off world’s blockbuster no 1 from generic competition

Ulrich Storz
Michalski Hütermann and Partner Patent Attorneys LLM, Germany

This presentation discusses the patent strategy underlying the world’s bestselling drug, AbbVie’s Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. The presentation will discuss this portfolio in detail, and comment on its strengths and weaknesses. Biography: Ulrich Storz received his PhD from the University of Münster in 2002 with a thesis in neurobiology. He then completed his training to become a German patent attorney. He joined the list of professional representatives before the European Patent Office in 2006. Dr. Storz’s main areas of practice are managing and enforcing patents and patent applications as well as drafting FTO analyses and opinions. He also provides advice on strategic patent issues, notably in life sciences (biotechnology, biophysics, biochemistry and microbiology), above all in the field of therapeutic antibodies. Ulrich Storz is regularly involved in major antibody opposition cases before the European Patent Office. He has also significant expertise in gene editing technologies including CRISPR, TALEN und ZFN, and also works in the field of CAR T cells, stem cell technologies, plant biosciences and enzymes. In recent years, he has also provided representation in a large number of sizeable due diligence projects in the field of pharmaceuticals and life sciences with a volume of EUR500,000 to EUR100m.

Biography

Ulrich Storz organizes the annual Rhineland Biopatent Forum and regularly publishes articles on patent issues relating to therapeutic antibodies in the magazine mAbs. He is a member of the Antibody Society, the Licensing Executive Society (LES), the Association for the Protection of Intellectual Property (GRUR) and the Association of Intellectual Property Experts (VPP).

Storz@mhpatent.de